Phloretin-liposome composition based on molecular inclusion complex and preparation method and application thereof

Through molecular inclusion technology and nano-liposome embedding, the water solubility and compatibility of root ferrin are improved, and the problems of poor solubility and compatibility are solved, and the stable delivery of root ferrin in cosmetics and healthy foods is achieved. .

CN118121544BActive Publication Date: 2024-11-26HEFEI HECHEN BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410110167.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-25
Publication Date
2024-11-26
Estimated Expiration
2044-01-25

AI Technical Summary

Technical Problem

The poor solubility, oxidation and discoloration and poor compatibility of rhizotin limit its application in cosmetics, healthy foods and medical beauty products.

Method used

Molecular inclusion technology is used to self-assemble root ferrin with cyclodextrin and/or cyclodextrin derivatives to form molecular inclusions, and embed them through nanoliposome technology to improve their water solubility and compatibility. sex.

Benefits of technology

It realizes efficient and steady-state delivery of root cerin, improves its stability and bioavailability in cosmetics, healthy foods, health products and biomedicine, and solves the problems of solubility and compatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118121544B_ABST
    Figure CN118121544B_ABST
Patent Text Reader

Abstract

The present invention discloses a phloretin-liposome composition based on molecular inclusion complex, and a preparation method and application thereof, wherein the phloretin-liposome composition based on molecular inclusion complex contains embedded carrier particles and molecular inclusion complexes loaded on the embedded carrier particles; wherein the embedded carrier particles are liposomes; and the molecular inclusion complex contains phloretin and cyclodextrin and / or cyclodextrin derivatives. The phloretin-liposome composition based on molecular inclusion complex can realize the efficient stabilization delivery of phloretin, which can not only effectively solve the pain point problems of phloretin in cosmetics, health foods, health products, medical beauty products and biomedical applications, but also improve the stability, compatibility and bioavailability of phloretin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biochemistry, and in particular to a phloretin-liposome composition based on molecular inclusion complexes, and a preparation method and application thereof. Background Art

[0002] Phloretin is a polyphenolic flavonoid functional active ingredient from natural plants. Its chemical name is trihydroxyphenol acetone 2,4,6-trihydroxy-3-(4-hydroxyphenyl) phenylpropiotone. It is mainly distributed in the peel and root bark of juicy fruits such as apples and pears, as well as in the juice of various vegetables. Domestic and foreign studies have shown that phloretin has a variety of health benefits, including but not limited to whitening and removing freckles, delaying aging, anti-glycation, anti-oxidation, anti-inflammatory, inhibiting sebum secretion, and removing acne. It is a potential active ingredient with broad application prospects. Phloretin is used in cosmetics such as facial masks, skin care creams and essences because of its activities such as lightening spots, whitening, removing acne, anti-mutagenicity, and anti-aging. Mizuma et al. found that phloretin can inhibit the effects of glucuronidation, promote the absorption of acetaminophen and 1-naphthol in the small intestine, and significantly improve its pharmacological activity. Therefore, phloretin has broad application prospects in the fields of health foods, cosmetics, health products, biopharmaceuticals, etc.

[0003] However, phloretin has poor solubility, is insoluble in water and oil, is easily oxidized and discolored, and has poor formula compatibility, making it difficult to disperse in cosmetic and food product formulations. These application pain points have seriously restricted the application of phloretin in industries such as cosmetics, health foods, and medical beauty. How to improve the water solubility of phloretin to increase its bioavailability is a major problem in its application.

[0004] Therefore, it is of great significance to provide a highly efficient and stable delivery product and preparation method of phloretin. Summary of the invention

[0005] The purpose of the present invention is to solve the problems of poor solubility of phloretin, easy oxidation discoloration, and poor compatibility, thereby providing a phloretin-liposome composition based on molecular inclusion complex and a preparation method and application thereof. The phloretin-liposome composition based on molecular inclusion complex can achieve efficient and stable delivery of phloretin, which can not only effectively solve the pain points of phloretin in cosmetics, health foods, health products, medical beauty products and biopharmaceutical applications, but also improve the stability, compatibility and bioavailability of phloretin.

[0006] In order to achieve the above-mentioned object, the first aspect of the present invention provides a phloretin-liposome composition based on a molecular inclusion compound, wherein the phloretin-liposome composition based on a molecular inclusion compound comprises an embedded carrier particle and a molecular inclusion compound loaded on the embedded carrier particle; wherein,

[0007] The embedded carrier particles are liposomes;

[0008] The molecular inclusion compound contains phloretin and cyclodextrin and / or cyclodextrin derivatives.

[0009] The second aspect of the present invention provides a method for preparing a phloretin-liposome composition based on a molecular inclusion complex, the preparation method comprising: providing an organic phase solution containing embedded carrier particles, providing a molecular inclusion complex solution containing a molecular inclusion complex, dripping the organic phase solution into the molecular inclusion complex solution under stirring at 25-65°C for embedding, and drying; wherein,

[0010] The embedded carrier particles are liposomes;

[0011] The molecular inclusion compound contains phloretin and cyclodextrin and / or cyclodextrin derivatives.

[0012] The third aspect of the present invention provides a phloretin-liposome composition based on molecular inclusion complex prepared by the above-mentioned preparation method.

[0013] The fourth aspect of the present invention provides an application of the above-mentioned phloretin-liposome composition based on molecular inclusion complex in cosmetics, health foods, health products, medical beauty products and biomedicine.

[0014] In the above technical scheme, the present invention uses molecular inclusion technology to self-assemble phloretin and cyclodextrin and / or cyclodextrin derivatives, forms a molecular inclusion complex through weak interaction between the two, and wraps the phloretin molecules in the hollow ring structure of cyclodextrin and / or cyclodextrin derivatives, converts the phloretin into a water-soluble or hydrophilic complex, thereby improving the stability of phloretin. Then, through nanoliposome technology, liposomes are used to encapsulate the phloretin-cyclodextrin molecular inclusion complex to further improve the compatibility and bioavailability of phloretin. The phloretin-liposome composition based on the molecular inclusion complex finally obtained realizes the efficient and stable delivery of phloretin.

[0015] At the same time, the preparation method of the molecular inclusion complex-based phloretin-liposome composition of the present invention is simple and easy to operate, can be mass-produced, saves time and material costs, and provides more possibilities for the design, development and innovative upgrading of cosmetics, health foods, health products, medical beauty products and biomedicines.

[0016] Other features and advantages of the present invention will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present invention but do not constitute a limitation of the present invention. In the accompanying drawings:

[0018] Figure 1 It is a schematic diagram of the embedding delivery technology of the phloretin-liposome composition based on molecular inclusion complex of the present invention;

[0019] Figure 2 This is a graph showing the evaluation results of the stability acceleration test of Application Example 1. DETAILED DESCRIPTION

[0020] The specific embodiments of the present invention are described in detail below. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.

[0021] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0022] The first aspect of the present invention provides a phloretin-liposome composition based on a molecular inclusion compound, wherein the phloretin-liposome composition based on a molecular inclusion compound comprises an embedded carrier particle and a molecular inclusion compound loaded on the embedded carrier particle; wherein:

[0023] The embedded carrier particles are liposomes;

[0024] The molecular inclusion compound contains phloretin and cyclodextrin and / or cyclodextrin derivatives.

[0025] The molecular inclusion complex-based phloretin-liposome composition provided by the present invention first uses the molecular inclusion technology to self-assemble phloretin and cyclodextrin and / or cyclodextrin derivatives, forms a molecular inclusion complex through the weak interaction between the two, and wraps the phloretin molecules in the hollow ring structure of cyclodextrin and / or cyclodextrin derivatives, converts the phloretin into a water-soluble or hydrophilic complex, and improves the stability of the phloretin. Then, through the nanoliposome technology, liposomes are used to embed the phloretin-cyclodextrin molecular inclusion complex, further improving the compatibility and bioavailability of phloretin. The finally prepared molecular inclusion complex-based phloretin-liposome composition achieves efficient and stable delivery of phloretin.

[0026] In a preferred embodiment of the present invention, in order to improve the stability of the phloretin-liposome composition based on the molecular inclusion complex, the phloretin-liposome composition based on the molecular inclusion complex further contains a strengthener.

[0027] In a preferred embodiment of the present invention, in order to improve the stability of the phloretin-liposome composition based on molecular inclusion complex, the enhancer is a polymer enhancer and / or an inorganic particle enhancer.

[0028] In a preferred embodiment of the present invention, in order to improve the stability of the phloretin-liposome composition based on molecular inclusion complex, the polymer enhancer is selected from one or more of chitosan, chitin, cellulose, protein, nucleic acid and starch.

[0029] In a preferred embodiment of the present invention, in order to improve the stability of the phloretin-liposome composition based on molecular inclusion complex, the inorganic particle strengthener is selected from one or more of silicon dioxide, titanium dioxide, calcium carbonate, calcium silicate and calcium phosphate.

[0030] In a preferred embodiment of the present invention, in order to make the phloretin-liposome composition based on molecular inclusion complex be better used in the corresponding field, the particle size of the inorganic particle enhancer is 5nm-100μm, preferably 10nm-50μm, and more preferably 10nm-10μm.

[0031] In a preferred embodiment of the present invention, in order to improve the stability of the phloretin-liposome composition based on the molecular inclusion complex, the liposome is selected from one or more of soybean lecithin, egg yolk lecithin, hydrogenated soybean lecithin, cholesterol and PEGylated phospholipids;

[0032] In a preferred embodiment of the present invention, in order to better encapsulate phloretin in the molecular inclusion complex and make phloretin have better water solubility, the cyclodextrin is selected from one or more of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin.

[0033] In a preferred embodiment of the present invention, in order to better encapsulate phloretin in the molecular inclusion complex and make phloretin have better water solubility, the cyclodextrin derivative is selected from one or more of methyl cyclodextrin, hydroxypropyl cyclodextrin, hydroxyethyl cyclodextrin, glucosyl cyclodextrin and sulfobutyl cyclodextrin.

[0034] In a preferred embodiment of the present invention, in order to better encapsulate phloretin in the molecular inclusion complex and make phloretin have better water solubility, and at the same time, the obtained phloretin-liposome composition based on the molecular inclusion complex has good stability, the mass ratio of phloretin, cyclodextrin and / or cyclodextrin derivatives and liposomes is 1:1-100:2-1000, preferably 1:3-50:4-100.

[0035] In a preferred embodiment of the present invention, the phloretin-liposome composition based on molecular inclusion complex has a final form of powder, solid particles, semi-solid paste or dispersion, etc., according to actual application requirements.

[0036] The second aspect of the present invention provides a method for preparing a phloretin-liposome composition based on a molecular inclusion compound, the preparation method comprising: providing an organic phase solution containing embedded carrier particles, providing a molecular inclusion compound solution, dripping the organic phase solution into the molecular inclusion compound solution under stirring at 25-65°C for embedding, and drying; wherein,

[0037] The embedded carrier particles are liposomes;

[0038] The molecular inclusion compound solution contains phloretin and cyclodextrin and / or cyclodextrin derivatives.

[0039] The preparation method of the phloretin-liposome composition based on molecular inclusion complex of the present invention is simple and easy to operate, can be mass-produced, saves time and material costs, and provides more possibilities for the design, development and innovative upgrading of cosmetics, health foods, health products, medical beauty products and biomedicine.

[0040] In a preferred embodiment of the present invention, the method for providing the organic phase solution is selected from one of an organic solvent injection method, a thin film dispersion method, a T-channel method, a cross-flow injection method and a microfluidics method, and more preferably an organic solvent injection method.

[0041] In a preferred embodiment of the present invention, when the method for providing the organic phase solution is an organic solvent injection method, the steps include: dissolving the embedded carrier particles in an organic solvent to obtain an organic phase solution containing the embedded carrier particles.

[0042] When the embedded carrier ions are complex liposomes, the method of providing the organic phase solution is an organic solvent injection method, and the steps include: dissolving the embedded carrier particles in an organic solvent, and then evaporating and drying to obtain the complex liposomes.

[0043] In a preferred embodiment of the present invention, in order to enable the liposome to better embed the molecular inclusion compound, the solvent of the organic phase solution is selected from one or more of ethanol, acetone, tetrahydrofuran, ethyl acetate, petroleum ether and dichloromethane.

[0044] In a preferred embodiment of the present invention, the method for providing the molecular inclusion compound solution is a complex solvent method, and the specific steps include:

[0045] (1) dissolving phloretin in an organic solvent to obtain a phloretin solution, and dissolving cyclodextrin and / or a cyclodextrin derivative in water to obtain a cyclodextrin and / or a cyclodextrin derivative solution;

[0046] (2) slowly adding the phloretin solution to the cyclodextrin and / or cyclodextrin derivative solution, stirring at a temperature of 25-65° C. to carry out an assembly reaction for 0.5-12 hours;

[0047] (3) distilling the product under reduced pressure and drying it to obtain a phloretin-cyclodextrin and / or cyclodextrin derivative inclusion complex solution.

[0048] In a preferred embodiment of the present invention, the organic solvent in the phloretin solution is selected from one or more of ethanol, acetone, tetrahydrofuran, ethyl acetate, petroleum ether and dichloromethane.

[0049] In a preferred embodiment of the present invention, in order to improve the stability of the phloretin-liposome composition based on the molecular inclusion complex, the preparation method further comprises: adding a reinforcing agent to the molecular inclusion complex solution to form a molecular inclusion complex dispersion.

[0050] In a preferred embodiment of the present invention, in order to improve the stability of the phloretin-liposome composition based on molecular inclusion complex, the enhancer is a polymer enhancer and / or an inorganic particle enhancer.

[0051] In a preferred embodiment of the present invention, in order to improve the stability of the phloretin-liposome composition based on molecular inclusion complex, the polymer enhancer is selected from one or more of chitosan, chitin, cellulose, protein, nucleic acid and modified starch and their derivatives.

[0052] In a preferred embodiment of the present invention, in order to improve the stability of the phloretin-liposome composition based on molecular inclusion complex, the inorganic particle strengthener is selected from one or more of silicon dioxide, titanium dioxide, calcium carbonate, calcium silicate and calcium phosphate.

[0053] In a preferred embodiment of the present invention, in order to make the phloretin-liposome composition based on molecular inclusion complex be better used in the corresponding field, the particle size of the inorganic particle enhancer is 5nm-100μm, preferably 10nm-50μm, and more preferably 10nm-10μm.

[0054] In a preferred embodiment of the present invention, in order to improve the dispersibility and compatibility of the embedded liposomes and enhance the stability of the phloretin-liposome composition based on the molecular inclusion complex, the drying conditions include: adding a drying protective agent during drying.

[0055] In a preferred embodiment of the present invention, the drying method is selected from one or more of rotary evaporation, freeze drying, spray drying, vacuum drying, double cone drying, heating drying and room temperature drying.

[0056] In a preferred embodiment of the present invention, in order to improve the dispersibility and compatibility of the embedded liposomes and enhance the stability of the phloretin-liposome composition based on molecular inclusion complexes, the drying protective agent is selected from one or more of oligosaccharides, polypeptides and proteins.

[0057] In a preferred embodiment of the present invention, in order to improve the dispersibility and compatibility of the embedded liposomes and enhance the stability of the phloretin-liposome composition based on the molecular inclusion complex, the drying protective agent is selected from one or more of sucrose, fructose, trehalose, mannitol, lactose, glucose, silk polypeptide, silk protein, maltodextrin and maltose.

[0058] In a preferred embodiment of the present invention, in order to enable cyclodextrin and / or cyclodextrin derivatives to better include phloretin molecules, the mass ratio of phloretin to cyclodextrin and / or cyclodextrin derivatives in the molecular inclusion complex solution is 1:1-100, preferably 1:3-50.

[0059] In a preferred embodiment of the present invention, in order to enable cyclodextrin and / or cyclodextrin derivatives to better include phloretin molecules, the cyclodextrin is selected from one or more of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin.

[0060] In a preferred embodiment of the present invention, in order to enable cyclodextrin and / or cyclodextrin derivatives to better include phloretin molecules, the cyclodextrin derivatives are selected from one or more of methyl cyclodextrin, hydroxypropyl cyclodextrin, hydroxyethyl cyclodextrin, glucosyl cyclodextrin and sulfobutyl cyclodextrin.

[0061] In a preferred embodiment of the present invention, in order to enable the liposome to better embed the molecular inclusion compound, the liposome is selected from one or more of soybean lecithin, egg yolk lecithin, hydrogenated soybean lecithin, cholesterol and PEGylated phospholipids.

[0062] In a preferred embodiment of the present invention, in order to enable the liposome to better embed the molecular inclusion compound, the mass ratio of phloretin to liposome is 1:2-1000, preferably 1:4-100.

[0063] In a preferred embodiment of the present invention, in order to remove the organic solvent in the phloretin-liposome composition based on molecular inclusion complex and enable the phloretin-liposome composition based on molecular inclusion complex to be better used, the preparation method also includes a particle size reduction process.

[0064] In a preferred embodiment of the present invention, the particle size reduction process may use an ultrasonic dispersion method.

[0065] In a preferred embodiment of the present invention, the phloretin-liposome composition based on molecular inclusion complex has a final form of powder, solid particles, semi-solid paste or dispersion, etc., according to actual application requirements.

[0066] The third aspect of the present invention provides a phloretin-liposome composition based on molecular inclusion complex prepared by the above-mentioned preparation method.

[0067] The fourth aspect of the present invention provides an application of the above-mentioned phloretin-liposome composition based on molecular inclusion complex in cosmetics, health foods, health products, medical beauty products and biomedicine.

[0068] The present invention will be described in detail below through examples, but the protection scope of the present invention is not limited thereto. In the following examples, the drugs and medicaments are all conventional commercial products.

[0069] Example 1

[0070] Preparation of phloretin / β-cyclodextrin-soy lecithin PC90 composition:

[0071] (1) Preparation of liposome organic phase solution: Weigh 1.0 g of soybean lecithin PC90 (phospholipid content of more than 90%) and dissolve it in 20 mL of ethanol to prepare soybean lecithin PC90-ethanol solution;

[0072] (2) Preparation of molecular inclusion complex solution: Weigh 100 mg of phloretin, add 20 mL of anhydrous ethanol to dissolve, and obtain a phloretin solution; weigh 0.50 g of β-cyclodextrin, add 60 mL of deionized water, and dissolve at 50° C. to obtain a β-cyclodextrin solution; slowly dropwise add the phloretin solution to the β-cyclodextrin solution, and raise the temperature to 60° C. for assembly. At the same time, magnetic stirring is performed at a speed of 500 rpm for 2 hours, and the product is concentrated by vacuum distillation to obtain 40 mL of phloretin / β-cyclodextrin inclusion complex solution;

[0073] (3) Liposome embedding: 20 mL of soybean lecithin PC90-ethanol solution was slowly dripped into 40 mL of phloretin / β-cyclodextrin inclusion complex solution under stirring at 60 °C and continued stirring for 30 min;

[0074] (4) Subsequent treatment: The product was rotary evaporated for 30 min, and then 1.0 g of mannitol and 1.0 g of trehalose were added, and ultrasonic dispersion was performed for 10 min to obtain 30 mL of concentrated solution, which was freeze-dried to obtain a phloretin / β-cyclodextrin-soy lecithin PC90 composition, which was recorded as B1.

[0075] Example 2

[0076] Preparation of Phloretin / γ-cyclodextrin-egg yolk lecithin / cholesterol composition:

[0077] (1) Preparation of composite liposome phase: 1.2 g of egg yolk phospholipid and 0.1 g of cholesterol were weighed and dissolved in 20 mL of petroleum ether, and rotary evaporated at 40° C. to prepare solid egg yolk phospholipid / cholesterol composite liposomes;

[0078] (2) Preparation of molecular inclusion complex solution: Weigh 100 mg of phloretin, add 20 mL of anhydrous ethanol to dissolve, and obtain a phloretin solution; weigh 0.80 g of γ-cyclodextrin, add 60 mL of deionized water, and dissolve at 50° C. to obtain a γ-cyclodextrin solution; slowly dropwise add the phloretin solution to the γ-cyclodextrin solution, and raise the temperature to 60° C. for assembly. At the same time, magnetic stirring is performed at a speed of 500 rpm for 2 hours, and the product is concentrated by vacuum distillation to obtain 40 mL of phloretin / γ-cyclodextrin inclusion complex solution;

[0079] (3) Liposome embedding: solid egg yolk phospholipid / cholesterol composite liposomes were added to 40 mL of phloretin / γ-cyclodextrin inclusion compound solution and ultrasonically dispersed for 30 min to ensure uniform dispersion;

[0080] (4) Subsequent treatment: The product was rotary evaporated for 30 min, and then 2.0 g of mannitol was added and ultrasonically dispersed for 10 min to obtain 20 mL of concentrated dispersion, which was vacuum dried at 35° C. to obtain a phloretin / γ-cyclodextrin-egg yolk lecithin / cholesterol composition, which was recorded as B2.

[0081] Example 3

[0082] Preparation of phloretin / methyl beta-cyclodextrin-hydrogenated soybean lecithin composition:

[0083] (1) Preparation of liposome organic phase solution: 1.2 g of hydrogenated soybean lecithin was weighed and dissolved in 20 mL of tetrahydrofuran to prepare a hydrogenated soybean lecithin-tetrahydrofuran solution;

[0084] (2) Preparation of molecular inclusion complex solution: Weigh 100 mg of phloretin, add 20 mL of anhydrous ethanol to dissolve, and obtain a phloretin solution; weigh 0.70 g of methyl β-cyclodextrin, add 60 mL of deionized water, and dissolve at 50° C. to obtain a methyl β-cyclodextrin solution; slowly dropwise add the phloretin solution to the methyl β-cyclodextrin solution, and raise the temperature to 60° C. for assembly. At the same time, magnetic stirring is performed at a speed of 500 rpm for 2 hours, and the product is concentrated by vacuum distillation to obtain 40 mL of phloretin / methyl β-cyclodextrin inclusion complex solution;

[0085] (3) Liposome embedding: 20 mL of hydrogenated soybean lecithin-tetrahydrofuran solution was slowly dripped into 40 mL of phloretin / β-cyclodextrin inclusion complex solution under stirring at 40°C, and stirring was continued for 30 min;

[0086] (4) Subsequent treatment: The product was rotary evaporated for 30 min, and then 2.0 g of maltodextrin was added and ultrasonically dispersed for 10 min to obtain 30 mL of concentrated solution, which was freeze-dried to obtain a phloretin / methyl β-cyclodextrin-hydrogenated soybean lecithin composition, which was recorded as B3.

[0087] Example 4

[0088] Preparation of phloretin / hydroxypropyl β-cyclodextrin-hydrogenated soybean lecithin-methylcellulose composition:

[0089] (1) Preparation of liposome organic phase solution: Weigh 1.2 g of hydrogenated soybean lecithin and dissolve it in 20 mL of ethanol to prepare a hydrogenated soybean lecithin-ethanol solution;

[0090] (2) Preparation of molecular inclusion complex dispersion: Weigh 100 mg of phloretin, add 20 mL of tetrahydrofuran to dissolve, and obtain a phloretin solution; weigh 0.70 g of hydroxypropyl β-cyclodextrin, add 60 mL of deionized water to dissolve, and obtain a hydroxypropyl β-cyclodextrin solution; slowly drop the phloretin solution into the hydroxypropyl β-cyclodextrin solution, and raise the temperature to 45°C for assembly. At the same time, stir magnetically at a speed of 500 rpm for 1.5 hours, and concentrate the product by vacuum distillation to obtain 40 mL of concentrated solution; weigh 0.1 g of methylcellulose, and dissolve it in the above 40 mL of concentrated solution to obtain a phloretin / hydroxypropyl β-cyclodextrin inclusion complex / methylcellulose dispersion;

[0091] (3) Liposome embedding: 20 mL of hydrogenated soybean lecithin-ethanol solution was slowly dripped into 40 mL of phloretin / hydroxypropyl β-cyclodextrin inclusion complex / methylcellulose dispersion under stirring at 60°C, and stirring was continued for 30 min;

[0092] (4) Subsequent treatment: The product was rotary evaporated for 30 min, and then 1.0 g of mannitol and 1.0 g of trehalose were added, and ultrasonic dispersion was performed for 10 min to obtain 30 mL of concentrated solution, which was freeze-dried to obtain a phloretin / hydroxypropyl β-cyclodextrin-hydrogenated soybean lecithin-methylcellulose composition, which was recorded as B4.

[0093] Example 5

[0094] Preparation of phloretin / methyl β-cyclodextrin-soy lecithin PC70 / cholesterol-silicon dioxide composition:

[0095] (1) Preparation of liposome organic phase solution: 1.2 g of soybean lecithin PC70 and 0.2 g of cholesterol were weighed in sequence and dissolved in 20 mL of ethanol to prepare a soybean lecithin / cholesterol-ethanol solution;

[0096] (2) Preparation of molecular inclusion complex dispersion: Weigh 100 mg of phloretin, add 20 mL of tetrahydrofuran to dissolve, and obtain a phloretin solution; weigh 0.70 g of methyl β-cyclodextrin, add 60 mL of deionized water to dissolve, and obtain a methyl β-cyclodextrin solution; slowly add the phloretin solution dropwise to the methyl β-cyclodextrin solution, and raise the temperature to 45° C. for assembly. At the same time, stir magnetically at a speed of 500 rpm for 1.5 hours, and concentrate the product by vacuum distillation to obtain 40 mL of concentrated solution; weigh 0.05 g of silica particles, and disperse them in the above 40 mL of concentrated solution to obtain a phloretin / methyl β-cyclodextrin inclusion complex / silicon dioxide dispersion;

[0097] (3) Liposome embedding: 20 mL of hydrogenated soybean lecithin-ethanol solution was slowly dripped into 40 mL of phloretin / methyl β-cyclodextrin inclusion complex / silica dispersion under stirring at 60°C, and stirring was continued for 30 min;

[0098] (4) Subsequent treatment: The product was rotary evaporated for 30 min, and then 2.0 g of mannitol was added and ultrasonically dispersed for 10 min to obtain 30 mL of concentrated solution, which was freeze-dried to obtain a phloretin / methyl β-cyclodextrin-soy lecithin / cholesterol-silicon dioxide composition, which was recorded as B5.

[0099] Example 6

[0100] Preparation of phloretin / hydroxypropyl β-cyclodextrin-hydrogenated soybean lecithin / egg yolk lecithin / cholesterol composition:

[0101] (1) Preparation of liposome organic phase solution: 0.6 g of hydrogenated soybean lecithin, 0.6 g of egg yolk lecithin and 0.2 g of cholesterol were weighed in sequence and dissolved in 20 mL of ethanol to prepare a hydrogenated soybean lecithin / egg yolk lecithin / cholesterol composite lipid-ethanol solution;

[0102] (2) Preparation of molecular inclusion complex solution: Weigh 100 mg of phloretin, add 20 mL of ethanol to dissolve, and obtain a phloretin solution; weigh 0.70 g of hydroxypropyl β-cyclodextrin, add 60 mL of deionized water to dissolve, and obtain a hydroxypropyl β-cyclodextrin solution; slowly drop the phloretin solution into the hydroxypropyl β-cyclodextrin solution, and raise the temperature to 55° C. for assembly. At the same time, stir magnetically at a speed of 500 rpm for 1.5 hours. Finally, concentrate the product to 40 mL by vacuum distillation to obtain a phloretin / hydroxypropyl β-cyclodextrin inclusion complex solution;

[0103] (3) Liposome embedding: Under stirring at 60°C, 20 mL of hydrogenated soybean lecithin / egg yolk lecithin / cholesterol complex lipid-ethanol solution was slowly dripped into the phloretin / hydroxypropyl β-cyclodextrin inclusion complex solution and continued stirring for 30 min;

[0104] (4) Subsequent treatment: The product was rotary evaporated for 30 min, and then 2.0 g of trehalose was added and ultrasonically dispersed for 10 min to obtain 30 mL of concentrated solution, which was freeze-dried to obtain a phloretin / hydroxypropyl β-cyclodextrin-hydrogenated soybean lecithin / egg yolk lecithin / cholesterol composition, recorded as B6.

[0105] Test Example 1

[0106] The dispersibility index (PDI) of the phloretin-liposome compositions B1-B6 based on molecular inclusion complexes prepared in Examples 1-6 was measured. The results are shown in Table 1.

[0107] Table 1

[0108]

[0109] It can be seen from the data in Table 1 that the phloretin-liposome compositions B1-B6 based on molecular inclusion complexes prepared in Examples 1-6 of the present invention all have good dispersibility. Relatively speaking, in a relatively simple lipid system, the particle size of the dispersed liposomes is relatively small, such as the products B1-B3 prepared in Examples 1-3; in a relatively complex system, the particle size of the liposomes is relatively large, especially after the stability enhancer is added to the molecular inclusion complex solution, the particle size increases significantly, and the dispersibility index increases, such as the products B4-B5 prepared in Examples 4-5, but the change is not large, indicating that the dispersibility is still good.

[0110] Test Example 2

[0111] Referring to the accelerated test model for cosmetics and foods, the molecular inclusion complex-based phloretin-liposome compositions B1-B6 prepared in Examples 1-6 were subjected to accelerated tests at 50°C, the retention rate of phloretin was analyzed and detected, and the stability was evaluated. The evaluation results are shown in Table 2.

[0112] Table 2

[0113]

[0114] It can be seen from the data in Table 2 that the stability of the products of control samples 2-3 in which phloretin is molecularly included by cyclodextrin is significantly better than that of the phloretin in control sample 1 which is not encapsulated, but the stability still needs to be improved. After the phloretin-liposome compositions B1-B6 based on molecular inclusion complexes prepared in Examples 1-6 of the present invention are double-encapsulated by liposomes, the stability of phloretin is greatly improved, which basically meets the requirements of cosmetics. After the stability enhancer is added to the molecular inclusion complex solution, the stability of phloretin is further improved.

[0115] Application Example 1

[0116] The application of the phloretin / hydroxypropyl β-cyclodextrin-hydrogenated soybean lecithin-methylcellulose composition B4 prepared in Example 4 in an essence lotion, using phloretin emulsified powder as a control sample, to prepare a control formula, the preparation process is as follows:

[0117] 1) Heat the phase A raw material to 75-80°C until the system melts into a liquid oil phase;

[0118] 2) Heat phase B to 75°C, start the IKA homogenizer, add phase A to phase B and homogenize at 2000 rpm for 1 to 2 minutes;

[0119] 3) Then, mechanically stir the emulsion formed by phase A and phase B, cool it to 60°C while stirring, and add phase C;

[0120] 4) The emulsion is stirred and cooled to below 50°C, and the components of phase D are added in sequence, stirred evenly, and the material can be discharged after cooling to obtain the essence emulsion;

[0121] Among them, the formulas of the above two emulsion products are Phase A-Phase D, see Table 3-4.

[0122] Table 3 Phloretin emulsified powder-essence lotion model formula

[0123]

[0124]

[0125] Table 4 Phloretin / hydroxypropyl β-cyclodextrin-hydrogenated soybean lecithin-methylcellulose composition B4 prepared in Example 4 - Essence emulsion model formula

[0126]

[0127]

[0128] The essence lotion prepared by the phloretin / hydroxypropyl β-cyclodextrin-hydrogenated soybean lecithin-methylcellulose composition B4 prepared in Example 4 and the essence lotion prepared by the phloretin emulsified powder were subjected to accelerated test evaluation in a 50°C oven. The experimental results are as follows: Figure 2 shown.

[0129] from Figure 2 It can be seen that after 5 days, obvious phloretin particles were precipitated in the control sample, while the essence emulsion prepared by the phloretin / hydroxypropyl β-cyclodextrin-hydrogenated soy lecithin-methylcellulose composition B4 prepared in Example 4 remained stable without phloretin precipitation. The experimental results show that the phloretin composite liposome encapsulation delivery preparation of the present invention can significantly improve its compatibility in cosmetic formulations, while improving the bioavailability of phloretin during consumer terminal use.

[0130] In summary, the phloretin-liposome composition based on molecular inclusion complex of the present invention greatly improves the solubility and water dispersibility of phloretin. At a temperature of 25 ° C, the solubility of phloretin in water is about 0.02 mg / g, the concentration is very low, it is difficult to reach the effective amount, and the insoluble phloretin is easy to aggregate in water, the dispersibility is very poor, and it is difficult to achieve the efficacy of phloretin, and the phloretin-liposome composition based on molecular inclusion complex of the present invention forms a molecular inclusion complex of phloretin and cyclodextrin or cyclodextrin derivatives. The water solubility of phloretin is greatly improved, and according to the solubility of phloretin in water, it can reach 1 mg / g, which is increased by 50 times; and for the phloretin-hydroxypropyl β-cyclodextrin molecular inclusion complex prepared in Example 4, the water solubility of phloretin is improved by more than 500 times, and after double embedding by liposomes, it still maintains excellent water dispersibility.

[0131] The molecular inclusion complex-based phloretin-liposome composition of the present invention greatly improves the stability of phloretin. From the stability evaluation results of test example 2, it can be seen that after phloretin is double-encapsulated in liposomes, the stability of phloretin is greatly improved, which is significantly better than the simple phloretin-cyclodextrin molecular inclusion complex, meeting the application pain point requirements of cosmetics and foods, thereby making it possible for phloretin to be widely used in cosmetics and health foods.

[0132] The molecular inclusion complex-based phloretin-liposome composition of the present invention significantly improves the compatibility of phloretin. Since phloretin has poor water solubility and oil solubility and poor dispersibility, it is difficult to disperse evenly during the application of cosmetics and foods, which seriously affects the stability of product formulas. The molecular inclusion complex-based phloretin-liposome composition of the present invention has good water dispersibility due to its double encapsulation structure, has excellent compatibility and stability in the formula, will not aggregate and separate, and solves the pain points of phloretin application.

[0133] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0134] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

[0135] In addition, various embodiments of the present invention may be arbitrarily combined, and as long as they do not violate the concept of the present invention, they should also be regarded as the contents disclosed by the present invention.

Claims

1. A phloretin-liposome composition based on molecular inclusion complex, characterized in that: The phloretin-liposome composition based on molecular inclusion complex contains embedded carrier particles and molecular inclusion complexes loaded on the embedded carrier particles; wherein, The embedded carrier particles are liposomes; The molecular inclusion complex contains phloretin and cyclodextrin and / or cyclodextrin derivatives; the phloretin-liposome composition based on the molecular inclusion complex also contains a strengthener; The reinforcing agent is a polymer reinforcing agent and / or an inorganic particle reinforcing agent; The polymer strengthening agent is methyl cellulose; The inorganic particle strengthening agent is silicon dioxide; The preparation method of the phloretin-liposome composition based on molecular inclusion complex comprises: providing an organic phase solution containing embedded carrier particles, providing a molecular inclusion complex solution, dripping the organic phase solution into the molecular inclusion complex solution under stirring at 25-65° C. for embedding, and drying; The method for preparing the phloretin-liposome composition based on molecular inclusion complex further comprises adding a strengthening agent into the molecular inclusion complex solution.

2. The phloretin-liposome composition based on molecular inclusion complex according to claim 1, characterized in that: The particle size of the inorganic particle strengthening agent is 5nm-100μm.

3. The phloretin-liposome composition based on molecular inclusion complex according to claim 1, characterized in that: The particle size of the inorganic particle strengthening agent is 10nm-50μm.

4. The phloretin-liposome composition based on molecular inclusion complex according to claim 1, characterized in that: The particle size of the inorganic particle strengthening agent is 10nm-10μm.

5. The phloretin-liposome composition based on molecular inclusion complex according to claim 1, characterized in that: The liposome is selected from one or more of soybean lecithin, egg yolk lecithin, hydrogenated soybean lecithin and PEGylated phospholipids; wherein, The liposomes may further contain cholesterol.

6. The phloretin-liposome composition based on molecular inclusion complex according to claim 1, characterized in that: The cyclodextrin is selected from one or more of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin.

7. The phloretin-liposome composition based on molecular inclusion complex according to claim 1, characterized in that: The cyclodextrin derivative is selected from one or more of methyl cyclodextrin, hydroxypropyl cyclodextrin, hydroxyethyl cyclodextrin, glucosyl cyclodextrin and sulfobutyl cyclodextrin.

8. The phloretin-liposome composition based on molecular inclusion complex according to claim 1, characterized in that: The mass ratio of the phloretin, cyclodextrin and / or cyclodextrin derivative, and liposome is 1:1-100:2-1000.

9. The phloretin-liposome composition based on molecular inclusion complex according to claim 1, characterized in that: The mass ratio of the phloretin, cyclodextrin and / or cyclodextrin derivative, and liposome is 1:3-50:4-100.

10. A method for preparing a phloretin-liposome composition based on molecular inclusion complex according to any one of claims 1 to 9, characterized in that: The preparation method comprises: providing an organic phase solution containing embedded carrier particles, providing a molecular inclusion compound solution, dripping the organic phase solution into the molecular inclusion compound solution under stirring at 25-65° C. for embedding, and drying; wherein, The embedded carrier particles are liposomes; The molecular inclusion compound solution contains phloretin and cyclodextrin and / or cyclodextrin derivatives; The preparation method further comprises: adding a strengthening agent to the molecular inclusion compound solution; The reinforcing agent is a polymer reinforcing agent and / or an inorganic particle reinforcing agent; The polymer strengthening agent is methyl cellulose; The inorganic particle strengthening agent is silicon dioxide.

11. The preparation method according to claim 10, characterized in that: The particle size of the inorganic particle strengthening agent is 5nm-100μm.

12. The preparation method according to claim 10, characterized in that: The particle size of the inorganic particle strengthening agent is 10nm-50μm.

13. The preparation method according to claim 10, characterized in that: The particle size of the inorganic particle strengthening agent is 10nm-10μm.

14. The preparation method according to claim 10, characterized in that: The drying conditions include: adding a drying protective agent during drying.

15. The preparation method according to claim 14, characterized in that: The desiccant is selected from one or more of sucrose, fructose, trehalose, mannitol, lactose, glucose, silk polypeptide, silk protein, maltodextrin and maltose.

16. The preparation method according to claim 10, characterized in that: The mass ratio of phloretin to cyclodextrin and / or cyclodextrin derivative in the molecular inclusion complex solution is 1:1-100.

17. The preparation method according to claim 10, characterized in that: The mass ratio of phloretin to cyclodextrin and / or cyclodextrin derivative in the molecular inclusion complex solution is 1:3-50.

18. The preparation method according to claim 10, characterized in that: The cyclodextrin is selected from one or more of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin.

19. The preparation method according to claim 10, characterized in that: The cyclodextrin derivative is selected from one or more of methyl cyclodextrin, hydroxypropyl cyclodextrin, hydroxyethyl cyclodextrin, glucosyl cyclodextrin and sulfobutyl cyclodextrin.

20. The preparation method according to claim 10, characterized in that: The liposome is selected from one or more of soybean lecithin, egg yolk lecithin, hydrogenated soybean lecithin and PEGylated phospholipids; wherein, The liposomes may further contain cholesterol.

21. The preparation method according to claim 10, characterized in that: The mass ratio of phloretin to liposome is 1:2-1000.

22. The preparation method according to claim 10, characterized in that: The mass ratio of phloretin to liposome is 1:4-100.

23. The preparation method according to claim 10, characterized in that: The solvent of the organic phase solution is selected from one or more of ethanol, acetone, tetrahydrofuran, ethyl acetate, petroleum ether and dichloromethane.

24. Use of the phloretin-liposome composition based on molecular inclusion complex according to any one of claims 1 to 9 in the preparation of cosmetics and medicines.